Precigen, Inc. Share Price & Technical Analysis
PGEN · $4.24 (-0.93%)
Healthcare / Biotechnology
$4.24
-0.93%
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors,…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
2% return in May, -4% avg return in past 3 year May month.
12% return in 2026, 65% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -14% | 5% | 11% | 2% | – | – | – | – | – | – | – | 12% |
| 25 | 17% | 31% | -12% | 7% | -19% | 8% | 21% | 165% | -27% | 24% | -7% | 8% | 215% |
| 24 | 0% | 7% | -6% | -13% | 8% | 7% | -6% | -27% | -18% | -11% | 13% | 22% | -26% |
| 23 | 0% | -19% | -8% | 9% | 0% | -8% | 27% | 29% | -22% | -21% | 0% | 18% | 4% |
| 22 | -30% | -15% | 0% | -38% | 0% | 0% | 14% | 47% | -5% | -24% | 13% | -21% | -59% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.43B
P/E ratio
—
52W high
$5.47
52W low
$1.28
Volume
17,13,082
Beta
1.07
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Precigen, Inc. share price today?
- Precigen, Inc. (PGEN) last traded around $4.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PGEN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PGEN. Download the app for real-time alerts.
- How can I analyze Precigen, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.